Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 17-23 , January 2010

Altered cholesterol and fatty acid metabolism in Huntington disease

  • Robert C. Block, MD, MPH

      Affiliations

    • Division of Epidemiology, Department of Community and Preventive Medicine and Preventive Cardiology Unit, Box 644, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14620, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • E. Ray Dorsey, MD

      Affiliations

    • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Christopher A. Beck, PhD

      Affiliations

    • Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • J. Thomas Brenna, PhD

      Affiliations

    • Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA
    • ,
  • Ira Shoulson, MD

      Affiliations

    • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

Received 18 October 2009 ,Accepted 29 November 2009.

References 

  1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72:971–983
  2. Rubinsztein DC, Amos W, Leggo J, et al. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet. 1994;7:525–530
  3. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–372
  4. Lanska DJ, Lavine L, Lanska MJ, Schoenberg BS. Huntington's disease mortality in the United States. Neurology. 1988;38:769–772
  5. Saher G, Brugger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005;8:468–475
  6. Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. Prog Neurobiol. 2006;80:165–176
  7. Valenza M, Rigamonti D, Goffredo D, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci. 2005;25:9932–9939
  8. Sipione S, Rigamonti D, Valenza M, et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet. 2002;11:1953–1965
  9. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Low plasma total cholesterol in patients with Huntington's disease and first-degree relatives. Mol Genet Metab. 2008;93:341–346
  10. Lutjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA. 1996;93:9799–9804
  11. Norlin M, Toll A, Bjorkhem I, Wikvall K. 24-hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). J Lipid Res. 2000;41:1629–1639
  12. Menkes JH, Hanoch A. Huntington's disease—growth of fibroblast cultures in lipid-deficient medium: a preliminary report. Ann Neurol. 1977;1:423–425
  13. Torrejon C, Jung UJ, Deckelbaum RJ. n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms. Prostaglandins Leukot Essent Fatty Acids. 2007;77:319–326
  14. Yanai A, Huang K, Kang R, et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci. 2006;9:824–831
  15. Singaraja RR, Hadano S, Metzler M, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet. 2002;11:2815–2828
  16. Underwood BR, Broadhurst D, Dunn WB, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain. 2006;129:877–886
  17. Steinberger J, Daniels SR, Eckel RH, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2009;119:628–647
  18. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet. 1985;27:62–67
  19. Lalic NM, Maric J, Svetel M, et al. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol. 2008;65:476–480
  20. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975–980
  21. Hunt MJ, Morton AJ. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res. 2005;166:220–229
  22. Rulifson EJ, Kim SK, Nusse R. Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. Science. 2002;296:1118–1120
  23. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2008;11:100–105
  24. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009;81:213–221
  25. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111:351–359
  26. McCann JC, Ames BN. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr. 2005;82:281–295
  27. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65:1582–1589
  28. Murck H, Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull. 2007;72:159–164
  29. Froyland L, Madsen L, Vaagenes H, et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res. 1997;38:1851–1858
  30. Esfandiari A, Soifiyoudine D, Paturneau-Jouas M. Inhibition of fatty acid beta-oxidation in rat brain cultured astrocytes exposed to the neurotoxin 3-nitropropionic acid. Dev Neurosci. 1997;19:312–320
  31. Ait-Said F, Elalamy I, Werts C, et al. Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta. 2003;1631:77–84
  32. Rhodes LE, Shahbakhti H, Azurdia RM, et al. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis. 2003;24:919–925
  33. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res. 2003;44:1984–1991
  34. Zimmer L, Hembert S, Durand G, et al. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett. 1998;240:177–181
  35. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry. 1998;44:235–242
  36. Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005;196:266–272
  37. Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT. The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med. 2005;3:11
  38. Moriguchi T, Lim SY, Greiner R, et al. Effects of an n-3-deficient diet on brain, retina, and liver fatty acyl composition in artificially reared rats. J Lipid Res. 2004;45:1437–1445
  39. Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP. Rapid b-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prost Leukot Essent Fatty Acids. 2009;80:157–163
  40. Philbrick DJ, Mahadevappa VG, Ackman RG, Holub BJ. Ingestion of fish oil or a derived n-3 fatty acid concentrate containing eicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. J Nutr. 1987;117:1663–1670
  41. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–361
  42. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27i–33i
  43. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond). 2009;116:1–16
  44. González-Périz A, Horrillo R, Ferré N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by {omega}-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009;23:1946–1957
  45. Harris WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–1654S
  46. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
  47. Ma TC, Buescher JL, Oatis B, et al. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett. 2007;411:98–103
  48. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem. 2008;283:25628–25637

PII: S1933-2874(09)00437-1

doi: 10.1016/j.jacl.2009.11.003

Journal of Clinical Lipidology
Volume 4, Issue 1 , Pages 17-23 , January 2010

Article Tools

* Image Usage & Resolution